Tuberculous Pericarditis is Multibacillary and Bacterial Burden Drives High Mortality

EBioMedicine

Volumn 2, Issue 11, 2015, Pages 1634-1639

  Pasipanodya, Jotam G ^d   Mubanga, Mwenya ^a   Ntsekhe, Mpiko ^a   Pandie, Shaheen ^a   Magazi, Beki T ^c   Gumedze, Freedom ^b   Myer, Landon ^b   Gumbo, Tawanda ^a,d   Mayosi, Bongani M ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c UNIVERSITY OF PRETORIA   (South Africa)

^d BAYLOR RESEARCH INSTITUTE   (United States)

Author keywords

Age; Bacterial burden; CD4+ counts; HIV; Therapy failure

Indexed keywords

STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADULT; AGED; ARTICLE; BACTERIAL LOAD; CD4 LYMPHOCYTE COUNT; COLONY FORMING UNIT; FEMALE; FOLLOW UP; HEART TAMPONADE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; MYCOBACTERIUM TUBERCULOSIS; PERICARDIAL EFFUSION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SPUTUM ANALYSIS; TUBERCULOUS PERICARDITIS; YOUNG ADULT; ARTIFICIAL INTELLIGENCE; COMORBIDITY; MICROBIOLOGY; PERICARDITIS, TUBERCULOUS; REGISTER; SPUTUM; STATISTICAL MODEL;

ADULT; AGED; ANTITUBERCULAR AGENTS; ARTIFICIAL INTELLIGENCE; BACTERIAL LOAD; CD4 LYMPHOCYTE COUNT; COMORBIDITY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PERICARDIAL EFFUSION; PERICARDITIS, TUBERCULOUS; REGISTRIES; SPUTUM; YOUNG ADULT;

EID: 84958832352     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2015.09.034     Document Type: Article

References (33)

1. Bowness R., Boeree M.J., Aarnoutse R., et al. The relationship between Mycobacterium tuberculosis MGIT time to positivity and CFU in sputum samples demonstrates changing bacterial phenotypes potentially reflecting the impact of chemotherapy on critical sub-populations. J. Antimicrob. Chemother. 2015, 70:448-455.
2. Breiman L. Statistical modeling: the two cultures. Stat. Sci. 2001, 16:199-231.
3. Breiman L., Friedman J., Olshen R., et al. Classification and regression trees 1984, Chapman & Hall/CRC, Washington DC.
4. Cherian G. Diagnosis of tuberculous aetiology in pericardial effusions. Postgrad. Med. J. 2004, 80:262-266.
5. Chigutsa E., Pasipanodya J.G., Visser M.E., et al. Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis. Antimicrob. Agents Chemother. 2015, 59:38-45.
6. Chigutsa E., Patel K., Denti P., et al. A time-to-event pharmacodynamic model describing treatment response in patients with pulmonary tuberculosis using days to positivity in automated liquid mycobacterial culture. Antimicrob. Agents Chemother. 2013, 57:789-795.
7. Davies G.R. Early clinical development of anti-tuberculosis drugs: science, statistics and sterilizing activity. Tuberculosis (Edinb.) 2010, 90:171-176.
8. Diacon A.H., Maritz J.S., Venter A., et al. Time to detection of the growth of Mycobacterium tuberculosis in MGIT 960 for determining the early bactericidal activity of antituberculosis agents. Eur. J. Clin. Microbiol. Infect. Dis. 2010, 29:1561-1565.
9. Epstein M.D., Schluger N.W., Davidow A.L., et al. Time to detection of Mycobacterium tuberculosis in sputum culture correlates with outcome in patients receiving treatment for pulmonary tuberculosis. Chest 1998, 113:379-386.
10. Fowler N.O. Tuberculous pericarditis. JAMA 1991, 266:99-103.
11. Giampaglia C.M., Martins M.C., Vieira G.B., et al. Multicentre evaluation of an automated bactec 960 system for susceptibility testing of Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 2007, 11:986-991.
12. Gumbo T. General principles of chemotherapy of infectious diseases. Goodman & Gilman's The Pharmacological Basis of Therapeutics 2011, McGraw Hill Medical, New York, NY. L.L. Brunton, B. Chabner, B. Knollmann (Eds.).
13. Gumbo T., Chigutsa E., Pasipanodya J., et al. The pyrazinamide susceptibility breakpoint above which combination therapy fails. J. Antimicrob. Chemother. 2014, 69:2420-2425.
14. Gumbo T., Pasipanodya J.G., Romero K., Hanna D., Nuermberger E. Forecasting accuracy of the hollow fiber system model of tuberculosis for clinical therapeutic outcomes. Clin. Infect. Dis. 2015, 61(suppl 1):S25-S31.
15. Jain M.K., Pasipanodya J.G., Alder L., et al. Pegylated interferon fractal pharmacokinetics: individualized dosing for hepatitis C virus infection. Antimicrob. Agents Chemother. 2013, 57:1115-1120.
16. Jumbe N., Louie A., Leary R., et al. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J. Clin. Invest. 2003, 112:275-285.
17. Kolibab K., Yang A., Parra M., et al. Time to detection of Mycobacterium tuberculosis using the MGIT 320 system correlates with colony counting in preclinical testing of new vaccines. Clin. Vaccine Immunol. 2014, 21:453-455.
18. Mayosi B.M., Burgess L.J., Doubell A.F. Tuberculous pericarditis. Circulation 2005, 112:3608-3616.
19. Mayosi B.M., Ntsekhe M., Bosch J., et al. Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis. N. Engl. J. Med. 2014, 371:1121-1130.
20. Mayosi B.M., Ntsekhe M., Volmink J.A., et al. Interventions for treating tuberculous pericarditis. Cochrane Database Syst. Rev. 2002.
21. Mayosi B.M., Wiysonge C.S., Ntsekhe M., et al. Clinical characteristics and initial management of patients with tuberculous pericarditis in the HIV era: the Investigation of the Management of Pericarditis in Africa (IMPI Africa) registry. BMC Infect. Dis. 2006, 6:2.z.
22. Mayosi B.M., Wiysonge C.S., Ntsekhe M., et al. Mortality in patients treated for tuberculous pericarditis in sub-Saharan Africa. S. Afr. Med. J. 2008, 98:36-40.
23. National Department of Health Republic of South Africa. National Antiretroviral Treatment Guidelines 2004, Jacana Publishers, (ISBN: 1-919931-69-4). (http://southafrica.usembassy.gov/media/2004-doh-art-guidelines.pdf (last accessed 9th August 2015)).
24. Pasipanodya J., Gumbo T. An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future. Antimicrob. Agents Chemother. 2011, 55:24-34.
25. Pasipanodya J.G., McIlleron H., Burger A., et al. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J. Infect. Dis. 2013, 208:1464-1473.
26. Pfyffer G.E., Welscher H.M., Kissling P., et al. Comparison of the Mycobacteria Growth Indicator Tube (MGIT) with radiometric and solid culture for recovery of acid-fast bacilli. J. Clin. Microbiol. 1997, 35:364-368.
27. Pusch T., Pasipanodya J.G., Hall R.G., et al. Therapy duration and long-term outcomes in extra-pulmonary tuberculosis. BMC Infect. Dis. 2014, 14:115.
28. Shadish R.S., Cook T.D., Campbell D.T. Experimental and quasi-experimental designs for generalized causal inference 2001, Belmont, Cengage Learning.
29. Shaw J.E., Pasipanodya J.G., Gumbo T. Meningeal tuberculosis: high long-term mortality despite standard therapy. Medicine (Baltimore) 2010, 89:189-195.
30. Shenje J., Adimora-Nweke I.F., Ross I.L., et al. Penetration of antibiotics in tuberculous pericarditis. EBiomedicine 2015, (Accepted).
31. Srivastava S., Pasipanodya J.G., Meek C., Leff R., Gumbo T. Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. J. Infect. Dis. 2011, 204:1951-1959.
32. Steinberg D., Colla P. CART: Tree-Structured Non-parametric Data Analysis 1995, Salford Systems, San Diego.
33. Theron G., Peter J., Calligaro G., et al. Determinants of PCR performance (Xpert MTB/RIF), including bacterial load and inhibition, for tb diagnosis using specimens from different body compartments. Sci. Rep. 2014, 4:5658.